Cat.NO.:A693915 Purity:98%
Product Details of Tenovin-6
| CAS No. : | 1011557-82-6 |
| Formula : |
C25H34N4O2S |
| M.W : |
454.63
|
| SMILES Code : | O=C(NC(NC1=CC=C(NC(CCCCN(C)C)=O)C=C1)=S)C2=CC=C(C(C)(C)C)C=C2 |
| Synonyms : |
Tenovin-6
|
| MDL No. : | MFCD11976906 |
| InChI Key : | BVJSXSQRIUSRCO-UHFFFAOYSA-N |
| Pubchem ID : | 24772043 |
Safety of Tenovin-6
| GHS Pictogram: |  |
| Signal Word: | Warning |
| Hazard Statements: | H302-H315-H319-H335 |
| Precautionary Statements: | P261-P305+P351+P338 |
Related Pathways of Tenovin-6
- epigenetics
Isoform Comparison
Biological Activity
| Description |
Tenovin-6, an analog of Tenovin-1, is an activator of p53 transcriptional activity. Tenovin-6 inhibits the protein deacetylase activities of purified human SIRT1, SIRT2, and SIRT3 with IC50s of 21 μM, 10 μM, and 67 μM, respectively. Tenovin-6 also inhibits dihydroorotate dehydrogenase (DHODH)[1].[2].
|
| Target |
|
In Vitro:
| Concentration | Treated Time | Description | References |
| H1299 cells | 10 μM | 48 h | Tenovin-6 in combination with metformin significantly inhibited cell growth. | PMC6433689 |
| Myeloma cells (U266) | 4 μM | 24 h | Tenovin-6 had minimal effects on the proliferation of U266 cells. | PMC5503455 |
| Burkitt’s lymphoma cells (BJAB) | 4 μM | 24 h | Tenovin-6 had minimal effects on the proliferation of BJAB cells. | PMC5503455 |
| Human hepatocarcinoma cell line Huh7 | 5 μM | 24 h | Tenovin-6 treatment significantly increased LC3B-II levels in Huh7 cells, and this increase was dose-dependent. | PMC5386474 |
| H1650 cells | 10 μM | 48 h | Tenovin-6 in combination with metformin significantly inhibited cell growth. | PMC6433689 |
| H460 cells | 10 μM | 48 h | Tenovin-6 in combination with metformin significantly inhibited cell growth. | PMC6433689 |
| Human lung adenocarcinoma epithelial cell line A549 | 10 μM | 24 h | Tenovin-6 treatment significantly increased LC3B-II levels in A549 cells, and this increase was dose-dependent. | PMC5386474 |
| Mouse embryonic fibroblasts (MEFs) | 5 μM | 24 h | Tenovin-6 significantly increased LC3A/B-II levels in wild-type MEF cells but not in ATG5−/− and ATG7−/− MEF cells. | PMC5386474 |
| Chronic lymphocytic leukaemia (CLL) cell | 10 µM | 24 h | To investigate the cytotoxic effect of Tenovin-6 on CLL cells, results showed that Tenovin-6 induced cell death without significant apoptotic features, and a significant increase in autophagosome number was observed. | PMC3817336 |
| Chronic lymphocytic leukaemia (CLL) cell | 10 µM | 4 h | To investigate the effect of Tenovin-6 on autophagy regulation in CLL cells, results showed that Tenovin-6 inhibited autophagy, leading to an increase in autophagosome number and accumulation of LC3 II and p62/Sequestosome 1. | PMC3817336 |
| PEL cells (BC3, BCBL-1, BCP1, JSC1) | 4 μM | 24 h | Tenovin-6 inhibited the proliferation of PEL cells, induced cell cycle arrest and apoptosis. | PMC5503455 |
| Chronic lymphocytic leukemia cells | 10 µM | 4 h or 24 h | To investigate the effects of Tenovin-6 on CLL cells, it was found to cause cell death through autophagy inhibition rather than inducing apoptosis via the p53 pathway. | PMC3817336 |
| A549 cells | 10 μM | 48 h | Tenovin-6 in combination with metformin inhibited cell proliferation more effectively than either agent alone. | PMC6433689 |
In Vivo:
| Administration | Dosage | Frequency | Description | References |
| NOD/SCID mice | PEL model | Intraperitoneal injection | 50 mg/kg | Daily until the end of the experiment | Tenovin-6 significantly inhibited the initiation and progression of PEL and extended the survival of mice. | PMC5503455 |
| NSG mice | Patient-derived xenograft model | Intraperitoneal injection | 50 mg/kg | Twice daily for 3 weeks | Combination therapy of TV-6 with gefitinib significantly inhibited tumor growth and prolonged remission | PMC6881627 |
Protocol
| Bio Calculators | ||||
| Preparing Stock Solutions |  |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.20mL 0.44mL 0.22mL |
11.00mL 2.20mL 1.10mL |
22.00mL 4.40mL 2.20mL |
|
| Dissolving Methods |
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
|
|||
Reviews
There are no reviews yet.